Ranolazine
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Ranolazine and local guidelines before prescribing.
Anti-anginal
Mechanism
Late sodium current inhibitor.
Uses
Chronic stable angina (add-on).
Dosing
- Ranolazine | 375 mg twice daily, then 500 mg, max 750 mg twice daily. Check QT and interactions.
Cardiology: Ischaemic Heart Disease (ACS)
Side effects
Dizziness, constipation, nausea, QT prolongation.
Interactions
Strong CYP3A4 inhibitors; simvastatin dose limit.
Contraindications and cautions
Liver cirrhosis, QT prolongation
Monitoring
ECG, renal function
Pregnancy and breastfeeding
Avoid
Renal and hepatic impairment
Avoid in severe hepatic impairment
Overdose and reversal
Supportive
Special advice
Does not lower heart rate or BP.
More from the textbook: uses, cautions and other points
- Ranolazine - blocks the late sodium current → reduces calcium overload; QT prolongation; many interactions.
Cardiology: Anatomy Physiology and Pharmacology - Anti-anginal drugs matched to the mechanism: beta blockers, calcium channel blockers or ranolazine. CCBs are best when spasm predominates.
Cardiology: Ischaemic Heart Disease (ACS)
Where it is discussed in the book
- Cardiology: Anatomy Physiology and Pharmacology (1 mention)
- Cardiology: Ischaemic Heart Disease (ACS) (2 mentions)
- Integrated cardiology chapter (2 mentions)